WTX 330
Alternative Names: WTX-330Latest Information Update: 09 May 2025
At a glance
- Originator Werewolf Therapeutics
- Class Antineoplastics; Immunotherapies; Interleukins
- Mechanism of Action Interleukin 12 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 30 Apr 2025 Phase-I/II clinical trials in Non-Hodgkin's lymphoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) (NCT06939283)
- 30 Apr 2025 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) (NCT06939283)
- 11 Mar 2025 Werewolf Therapeutics plans a phase I/II trial for Solid tumours (Parenteral), by the end of first quarter of 2025